GeneDx Faces Securities Class Action Over Fabric Genomics Acquisition

The legal action, filed by Robbins LLP, centers on claims that GeneDx misrepresented the integration of the AI-driven genomic interpretation firm. According to the lawsuit, leadership touted the acquisition as a catalyst for recurring software-based revenue and operational synergies, while allegedly disregarding significant underlying issues with the business. These public assurances reportedly created a distorted view of the company’s financial trajectory during the class period.

The discrepancy between company projections and operational reality became apparent on May 4, 2026, when GeneDx released its first-quarter financial results. The company missed revenue targets for its exome and genome testing lines and issued a sharp reduction in its full-year guidance, dropping from a range of $540–$550 million to $475–$490 million. Additionally, GeneDx disclosed a $31.2 million impairment loss directly tied to the Fabric Genomics acquisition. Following these disclosures, the company’s stock price plummeted by $33.42, or approximately 49.2%.